Vizex Investments Ltd
financial consultations

Last news

Transenterix announces 1st US sale

Nov 13, 2017 14
November 13th. Transenterix Inc…

We no longer recommend Array Biopharma Inc

Nov 11, 2017 10
November 11th 2017. We are withdrawing…

FDA approves Transenterix Senhance robot for commercial sales in the U.S.

October 14th. TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced the Company has received FDA 510(k) clearance for the Senhance™ Surgical Robotic System. With this clearance, the Senhance becomes the first new market entrant into the field of abdominal surgical robotics since 2000. The approval opens the way for Transenterix to the biggest robotic surgery market - the U.S. And the company along with Intuitive Surgical became the second major player on the global market.

Вайзекс Инвестментс ООД © 2015 | Всички права запазени